Dapagliflozin for Atrial Fibrillation

Cardiovasc Drugs Ther. 2024 Feb;38(1):1-3. doi: 10.1007/s10557-024-07543-7. Epub 2024 Feb 6.

Authors

Na Li¹, Mihail G Chelu², Yochai Birnbaum³

Affiliations

¹ Department of Medicine (Section of Cardiovascular Research), Baylor College of Medicine, Houston, USA.
² Department of Medicine (Section of Cardiology), Baylor College of Medicine, 7200 Cambridge Street, MS BCM620, Houston, TX, 77030, USA.
³ Department of Medicine (Section of Cardiology), Baylor College of Medicine, 7200 Cambridge Street, MS BCM620, Houston, TX, 77030, USA. ybirnbau@bcm.edu.

PMID: 38319469
DOI: 10.1007/s10557-024-07543-7

No abstract available

Publication types

Editorial

MeSH terms

Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Benzhydryl Compounds / adverse effects
Glucosides / adverse effects
Humans

Substances

dapagliflozin
Benzhydryl Compounds
Glucosides

Grants and funding